



BD Breaks Ground on New BioTech Manufacturing Facility in Hungary

Tatabánya Plant to Produce Reagents for BioTech Research

Tatabánya, Hungary, 12 Nov. 2015 — BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today held a groundbreaking ceremony for a new research reagents manufacturing facility in Tatabánya, Hungary. The new 6 billion Hungarian Forints (HUF) investment by BD is expected to generate more than 100 new high-tech jobs.

The new facility is constructed on the company's existing site in the Tatabánya Industrial park of Komárom-Esztergom County. Construction will be completed by the beginning of 2017 and will be fully operational in 2018. Up to 60 percent of the new jobs will require a university and post-graduate degree in the areas of biology, biochemistry or supply chain. BD will provide comprehensive training programs to ensure the success of the new hires.

“With a highly skilled workforce and strong support of local public officials, Hungary is a place where we plan to have a long-term presence,” said Claude Dartiguelongue, worldwide president of Biosciences for BD Life Sciences. “Our new facility will create more than 100 jobs in the field of biotechnology, bringing new growth opportunities to the area.”

BD established its presence in Hungary in 2008, opening a plant producing pre-fillable syringes. Today, BD Hungary employs 650 associates and exports pre-fillable syringes for use by pharmaceutical and biotech companies.

About BD

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.

###